Accordingly, treatment of ccRCC patients with anti-programmed cell death 1 (PD-1), an immune checkpoint inhibitor, positively correlates with reduced tumor burden and therefore is clinically beneficial [169, 170]. The gene discussed is PDCD1; the disease is nonpapillary renal cell carcinoma.